QT interval prolongation and the risk of torsades de pointes: essentials for clinicians
- PMID: 24020938
- DOI: 10.1185/03007995.2013.840568
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians
Abstract
Objective: QT interval prolongation signifies an increased risk of the life-threatening arrhythmia torsades de pointes (TdP). The purpose of this paper is to review the diverse methods for assessing and monitoring the risk of TdP, discuss risk factors for TdP, and recommend interventions that may mitigate the risk of TdP.
Methods: A non-systematic search of PubMed (through March 2013) was conducted to determine the optimal approach to assessing and monitoring QT interval, prevention of TdP, and to identify risks factors for TdP. Papers known to the authors were included, as were scientific statements. Articles were chosen based on the judgment of the authors.
Results: Risk factors for drug-induced TdP include hypokalemia, female sex, drug-drug interactions, advancing age, genetic predisposition, hypomagnesemia, heart failure, bradycardia, and corrected QT (QTc) interval prolongation. Many risk factors, including hypokalemia, use of QT-interval-prolonging drugs, and drug interactions are potentially modifiable and should be corrected in persons at risk for QT interval prolongation. Given the variable onset of TdP following initiation of QT-interval-prolonging drugs, careful and regular monitoring of electrocardiography (EKG) and electrolytes are necessary. Patients at risk for QT interval prolongation should be educated to go directly to the emergency room if they experience palpitations, lightheadedness, dizziness or syncope. When the QTc interval is 470-500 ms for males, or 480-500 ms for females, or the QTc interval increases 60 ms or more from pretreatment values, dose reduction or discontinuation of the offending drug should be considered where possible, and electrolytes corrected as needed. Furthermore, if the QTc interval is ≥500 ms, the offending drug should be discontinued, and continuous EKG telemetry monitoring should be performed, or the 12-lead EKG should be repeated every 2-4 hours, until the QT interval has normalized.
Conclusions: Close monitoring for QTc prolongation is necessary to prevent TdP. The recommendations in this paper are limited by the available evidence and additional studies are needed to better define the approach to monitoring.
Similar articles
-
Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.Clin Toxicol (Phila). 2015 May;53(4):204-9. doi: 10.3109/15563650.2015.1013547. Epub 2015 Feb 23. Clin Toxicol (Phila). 2015. PMID: 25706450
-
Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?J Electrocardiol. 2009 Jul-Aug;42(4):353-357.e1. doi: 10.1016/j.jelectrocard.2009.01.005. Epub 2009 Mar 3. J Electrocardiol. 2009. PMID: 19261294
-
Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation.J Am Coll Cardiol. 2009 Jul 7;54(2):143-9. doi: 10.1016/j.jacc.2009.03.043. J Am Coll Cardiol. 2009. PMID: 19573731
-
QTc prolongation, torsades de pointes, and psychotropic medications.Psychosomatics. 2013 Jan-Feb;54(1):1-13. doi: 10.1016/j.psym.2012.11.001. Psychosomatics. 2013. PMID: 23295003 Review.
-
Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.Z Gerontol Geriatr. 2018 Jan;51(1):41-47. doi: 10.1007/s00391-016-1155-5. Epub 2016 Nov 22. Z Gerontol Geriatr. 2018. PMID: 27878411 Review. English.
Cited by
-
Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients.Vasc Health Risk Manag. 2024 Feb 1;20:27-37. doi: 10.2147/VHRM.S438899. eCollection 2024. Vasc Health Risk Manag. 2024. PMID: 38318252 Free PMC article.
-
Fluoroquinolones do not provide added risk of out-of-hospital cardiac arrest: a nationwide study.Open Heart. 2024 Jan 12;11(1):e002520. doi: 10.1136/openhrt-2023-002520. Open Heart. 2024. PMID: 38216172 Free PMC article.
-
Personalizing electrolytes in the dialysis prescription: what, why and how?Clin Kidney J. 2023 Oct 13;17(1):sfad210. doi: 10.1093/ckj/sfad210. eCollection 2024 Jan. Clin Kidney J. 2023. PMID: 38186873 Free PMC article. Review.
-
Haloperidol-induced sudden cardiac arrest in a recently detected HIV and hepatitis C patient: A unique case report.SAGE Open Med Case Rep. 2023 Dec 20;11:2050313X231220792. doi: 10.1177/2050313X231220792. eCollection 2023. SAGE Open Med Case Rep. 2023. PMID: 38130911 Free PMC article.
-
Comparing the efficacy and safety of medications in adults with hypertrophic cardiomyopathy: a systematic review and network meta-analysis.Front Cardiovasc Med. 2023 Aug 14;10:1190181. doi: 10.3389/fcvm.2023.1190181. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37645523 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
